VR Logo

Amarin Corporation plc (AMRN) download report


Healthcare | Biotechnology & Pharma Research

Amarin Corporation plc (AMRN) Premium Coverage

52 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates.

IPO Date: 01-Apr-1993

Pres, CEO & Director: Mr. Karim Mikhail

CFO, Sr. VP & Assistant Sec.: Mr. Michael W. Kalb CPA

Listing: NASDAQ: AMRN

Country: Ireland

Headquarters: Dublin,

Website: https://www.amarincorp.com

Key Facts

Market cap: $746.38 Mln

Revenue (TTM): $535.65 Mln

Earnings (TTM): $-22.21 Mln

Cash: $362.56 Mln

Total Debt: $10.40 Mln

Insider's Holding: 1.29%

Liquidity: Low

52 Week range: $1.11 - 5.97

Shares outstanding: 397,008,000

10 Years Aggregate:

  • CFO: $-768.27 Mln
  • EBITDA: $-621.31 Mln
  • Net Profit: $-820.54 Mln

Stock Performance

Time Period Amarin (AMRN) S&P BSE Sensex S&P Small-Cap 600
YTD-43.03-9.49-17.79
1 month36.17-2.87-2.72
3 months-41.28-8.59-12.17
1 Year-57.710.81-15.82
3 Years-53.4310.397.14
5 Years-10.5911.116.20
10 Years-17.3912.0010.33
As on 24-Jun-2022
Year Amarin (AMRN) S&P Small-Cap 600 S&P BSE Sensex
2021-31.0825.2721.99
2020-77.199.5715.75
201957.5320.8614.38
2018237.15-9.705.87
201730.1911.7327.91
201662.9624.741.95
201592.92-3.36-5.03